Gujarat Themis Biosyn Ltd
GUJT

Gujarat Themis Biosyn Ltd (GUJTHEMIS)

₹428.455.54%

Key Stats

₹416.2
Day's Price Range
₹436.95
₹250
52-Week Price Range
₹692
1 Month Return-3.71 %
3 Month Return7.96 %
1 Year Return43.41 %

Company Financials

  • Annual
Value in ₹ crore

Peer Comparsion

PE
Rank 76
EPS
Rank 77
BVPS
Rank 83
Dividend Yield
Rank 42
ROE
Rank 5
53.83%
Price To Book Ratio
Rank 64
Debt To Asset
Rank 83

Company Information

Promoted by Kantilal Shah and the Gujarat Industrial Investment Corporation Gujarat Themis Biosyn GTBL was incorporated in Dec.81 as a public limited company.Initially manufacturing the antibiotic erythromycin GTBL obtained licences to manufacture bulk drugs like rifampicin cephalexin griseofulvin and their formulations in 1990. However problems relating to purity levels yield and imports put the company in the red and it became a BIFR case in 1990. Subsequently it was taken over by a group consisting of Lyka Labs Themis Chemicals Kopran and Cadila. Also Yuhan Corporation South Korea brought in technology and finance for running GTBL.During 199596 the paidup share capital increased from Rs 11.25 crores to Rs 11.60 crores after allotment of 350000 Equity shares of Rs 10 each at a premium of Rs 20 per share to the financial institutions by way of conversion of fund interst term loan. During the year installed capacity of rifamysinS was increased to 90 mtpa and expansion of rifampicin was achieved to the maximum capacity of 120 mtpa. It also commenced operations of its new pharmaceutical division and launched a wide range of antituberculosis products and other antibiotics.The company is constantly identifying new areas for diversification and also capacity expansion of exisiting product in order to further reduction in cost of production and increase in turnover.
OrganisationGujarat Themis Biosyn Ltd
HeadquartersVAPI
IndustryPharmaceuticals